PTC Therapeutics prices USD 500 million 0% convertible senior notes due 2031

By Public Technologies
  • PTC Therapeutics priced USD 500 million of 0% Convertible Senior Notes due 2031 in a Rule 144A private placement.
  • Initial purchasers hold a 13-day option to buy up to an additional USD 50 million, lifting potential total issuance to USD 550 million.
  • Net proceeds estimated at USD 486.8 million, or USD 535.5 million if the option is fully exercised.
  • Proceeds earmarked to refinance 2026 convertibles, including about USD 328.8 million cash to repurchase USD 222 million principal amount in concurrent transactions.
  • Notes carry a USD 107.48 conversion price, a 40% premium to the June 15 close of USD 76.77.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606152314PR_NEWS_USPR_____NY84566) on June 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.